Translation of "Onychomykose" in English

Other clinical may signs include kerion, pseudomycetoma and onychomycosis.

More than 20 percent of the population is affected by nail mycosis (onychomycosis).

A combination of topical and oral antifungals is widely used to treat onychomycosis.

Nail fungus infections, also referred to as onychomycosis, are extremely common.

The nail fungus infection is also known as onychomycosis.

Fungal infections, such as onychomycosis, can also occur in or around the nail bed.

Onychomycosis — it is not just a cosmetic problem.

Onychomycosis (fungal infection of the nails) occurs as a result of parasitic fungi.

In addition, the drops are employed by onychomycosis.

This is the explanation as to why the problem onychomycosis cannot be solved by a modern short-term drug therapy.

This is the first report of human onychomycosis caused by this zoophilic fungus in Germany.

Possibly, this therapeutic way of proceedings gives rise to an increased interest by the dermatologist concerning the treatment of the onychomycosis.

The therapy depends on the number of fingers affected by onychomycosis type and severity of damage.

In fall of last year, systematical fluconazole has got an authorization extension for the indication "Onychomycosis".

These studies demonstrated that oral fluconazole is an effective and well-tolerated antimycotic agent against Tinea corporis, Tinea cruris, Tinea pedis, Tinea versicolor and onychomycosis.

Dermatomycoses include Tinea pedis, Tinea corporis, Tinea cruris, Tinea versicolor, Tinea unguinium (onychomycosis) and dermal Candida infections.

The CHMP agreed that Diflucan can be used for the following conditions: mucosal and invasive candidiasis, genital candidiasis (trush), crypotococcal meningitis, dermatomycosis, coccidiodomycosis and onychomycosis.

Based on the state of the art set forth above, and the above-mentioned requirements, the underlying problem of the invention is to devise a nail lacquer for treating onychomycosis which can be applied topically to the affected nail area, as an easily removable film, which provides good liberation of the active principle, and which affords good diffusion of the antimycotic active principle into the regions of the nail which are affected by onychomycosis, without attacking healthy nail material.

Currently, the society provides under the canopy of Arbeitsgemeinschaft der Medizinisch-Wissenschaftlichen Fachgesellschaften (AWMF) 6 guidelines (for the electronic version see www.awmf-leitlinien.de), namely „tinea of glabrous skin“, „onychomycosis“, „vulvovaginal candidosis“, „cutaneous candidosis“, “oral candidosis”, and “tinea capitis”.

The lesion of nails with fungi, which in medical practice is called onychomycosis, is a fairly common disease, and in all countries of the world.

The Deutschsprachige Mykologische Gesellschaft has established the guidelines "Onychomycosis" in cooperation with the Deutsche Dermatologische Gesellschaft (German Dermatological Society) and the Berufsverband der Deutschen Dermatologen (Professional Association of German Dermatologists).

With the fungi-determined nail disease, onychomycosis, the nail plates change color into yellow-brownish, they deform and get brittle.

In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.

As further therapy option, there is now systemical Fluconazole (Diflucan® Derm) available which received an authorization extension for the indication "Onychomycosis" in fall of last year.

For onychomycosis: Adults and teenagers 250 mg once a day for 6 to 12 weeks.

It is true that also in the year 2000 a breakthrough in the therapy of the onychomycosis cannot be announced but there are new promising therapy-concepts and -patterns with the support of systemical antimycotics.

The compounds according to the invention can additionally be used for the treatment of primary and secondary Raynaud's phenomenon, of microcirculation impairments, claudication, peripheral and autonomic neuropathies, diabetic microangiopathies, diabetic retinopathy, diabetic ulcers on the extremities, CREST syndrome, erythematosis, onychomycosis and rheumatic disorders.

The compounds according to the invention can additionally be used for the treatment of primary and secondary Raynaud's phenomenon, of microcirculation impairments, claudication, peripheral and autonomic neuropathies, diabetic microangiopathies, diabetic retinopathy, diabetic ulcers on the extremities, gangrene, CREST syndrome, erythematosis, onychomycosis, rheumatic disorders and for promoting wound healing.

Furthermore, the compounds according to the invention can be used for the treatment and/or prevention of primary and secondary Raynaud's phenomenon, of microcirculation impairments, claudication, tinnitus, peripheral and autonomic neuropathies, diabetic microangiopathies, diabetic retinopathy, diabetic ulcers on the extremities, gangrene, CREST syndrome, erythematosis, onychomycosis and rheumatic disorders.